|
| | | | | | | | | | |
| Name | Indication | Economics | Approved | MOA | IP | | Price | 76.08 | |
| Biktarvy (bictegravir/emtricitabine/TAF) | HIV | 1 | | Integrase | 2033 | | Shares | 1248 | Q123 |
| Genvoya (elvitegravir/TAF/emtricitabine/cobicistat) | HIV | 1 | | Integrase | 2027 | | MC | 94947.84 | |
| Descovy (TAF/emtricitabine) | HIV | 1 | | NRTI+NRTI | 2025 | | Cash | 7199 | Q123 |
| Symtuza (darunavir/emtricitabine/TAF) | HIV | 1 | | PI+NRTI | | | Debt | 25239 | Q123 |
| Stribild (Truvada/elvitegravir/cobicistat) | HIV | 1 | 8/27/2012 | Integrase | 2021 | | EV | 112987.84 | |
| Veklury (remdesivir) | COVID-19 | 1 | | NRTI | | | | | |
| Sovaldi (sofosbuvir) | HCV | 1 | 12/6/2013 | | ABT, BMY | | | | |
| Atripla (tenofovir+ETC+Sustiva) | HIV | 62%, BMY | 6/12/2006 | NNRTI+NRTI | 2017+ | | CEO: Daniel O'Day | | |
| Emtriva (emtricitabine) | HIV | 1 | 2/7/2003 | NRTI | 2021? | | CMO: Merdad Parsey | | |
| Hepsera (adefovir) | HBV | 1 | 9/23/2002 | | | | EVP, Research: Flavius Martin | | |
| Letairis (ambrisentan) | PAH | GSK | 6/15/2007 | ERA | 2015/2016? | | | | |
| Ambisome | Fungal Infection | EU, Astellas GSK | 1/8/1997 | Antifungal | | | | | |
| Tecartus | | | | | | | | | |
| Yescarta | | | | | | | | | |
| Hepcludex | | | | | | | | | |
| Sunlenca (lenacapavir) | HIV | 1 | 12/22/2022 | | | | | | |
| Complera (rilpivirine+Truvada) | HIV | JNJ | | | MRK, GSK/PFE | | | | |
| Trodelvy (sacituzumab govitecan) | mBC, mUC | | | | | | | | |
| Harvoni (ledipasvir/sofosbuvir) | HCV | 1 | | | ABBV, JNJ, BMY, MRK | | | | |
| Zydelig (idelalisib) | CLL/FL | 1 | EMEA rec | | | | | | |
| Tamiflu | Influenza | ROG VX | 10/27/1999 | | | | | | |
| | | | Phase | Mechanism | Competition | | | | |
| MB272 | | | I | BTLA (B-cell/T-cell attenuator) | | | | | |
| MB151 | | | I | PD-1 agonist | | | | | |
| domvanalimab | Oncology | RCUS | II | TIGIT mab | | | | | |
| GS-5245 | COVID-19 | | | | | | | | |
| GS5806 | RSV | 1 | II | Fusion Inhibitor | | | | | |
| GS9973 | CLL | 1 | II | Syk kinase inhibitor | | | | | |
| GS9451 | HCV | 1 | II | NS3 Protease Inhibitor | | | | | |
| GS5885 | HCV | 1 | IIb | NS5A inhibitor | | | | | |
| GS6615 | LQT3, Hypertrophic Cardiomyopathy, Vtach/Vfib | 1 | II | Late Sodium Current Inhibitor | ? | | | | |
| GS9667 | diabetes/dyslipidemia | | I | partial A1 adenosine agonist | | | | | |
| | | | | | | | | | |
| | | | 2006: Acquires Corus? | | | | | | |
| | | | 2/8/07: Discontinues GS9132. | | | | | | |
| | | | February 23 2007: GS9137 integrase p2 interim data 24-week efficacy | | | | | | |
| | | | 2007: GS9160, GS9224 discontinued. | | | | | | |
| | | | 9/2009: Submitted MAA to EMEA for Truvada+rilpivirine. | | | | | | |
| | | | 6/2010: acquired private co CGI for $91m cash & $30m pot milestones, for small molecule inhibitors of spleen tyrosine kinase (Syk), lead preclinical compound for inflam diseases such as RA. | | | | | | |
| | | | 12/10/2010: Discontinued GS9219: a nucleotide analogue for CLL, NHL, MM due to safety concerns. | | | | | | |
| | | | 12/23/2010: Acquires Arresto Biosciences. | | | | | | |
| | | | Darusentan failed. | | | | | | |
| | | | GS9190 and GS9191 discontinued. | | | | | | |
| | | | GS9131/GS9148 unclear. | | | | | | |
| | | | Cicletanine discontinued. | | | | | | |
| | | | GS9256 (HCV protease) discontinued? | | | | | | |
| | | | GS9260 (TLR7 agonist for HCV) discontinued? | | | | | | |
| | | | GS6620 and GS9669, Polymerase for HCV discontinued? | | | | | | |
| | | | 7/23/2010: Acquires Arresto Biosciences. | | | | | | |
| | | | GS9620, GS9260 (TLR-7 agonists) discontinued for HCV. | | | | | | |
| | | | | | | | | | |
| | | | 6/2015: GS-5806 results expected. | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | 8/4/22: MiroBio acquisition announcement for $405m. | | | | | | |
| | | | | | | | | | |
| | | | 9/13/22: $20m donation | | | | | | |
| | | | 9/15/22: WHO expands recommendation for Veklury | | | | | | |